JP2003522724A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522724A5
JP2003522724A5 JP2000543139A JP2000543139A JP2003522724A5 JP 2003522724 A5 JP2003522724 A5 JP 2003522724A5 JP 2000543139 A JP2000543139 A JP 2000543139A JP 2000543139 A JP2000543139 A JP 2000543139A JP 2003522724 A5 JP2003522724 A5 JP 2003522724A5
Authority
JP
Japan
Prior art keywords
acid
carboxylic acid
group
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000543139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522724A (ja
Filing date
Publication date
Priority claimed from US09/057,260 external-priority patent/US5962488A/en
Application filed filed Critical
Publication of JP2003522724A publication Critical patent/JP2003522724A/ja
Publication of JP2003522724A5 publication Critical patent/JP2003522724A5/ja
Pending legal-status Critical Current

Links

JP2000543139A 1998-04-08 1998-11-16 医薬製剤のための酸化防止剤−安定剤系 Pending JP2003522724A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/057,260 1998-04-08
US09/057,260 US5962488A (en) 1998-04-08 1998-04-08 Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
PCT/US1998/024471 WO1999052529A1 (en) 1998-04-08 1998-11-16 Antioxidant stabilizer system for pharmaceutical formulations

Publications (2)

Publication Number Publication Date
JP2003522724A JP2003522724A (ja) 2003-07-29
JP2003522724A5 true JP2003522724A5 (enExample) 2006-01-05

Family

ID=22009506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000543139A Pending JP2003522724A (ja) 1998-04-08 1998-11-16 医薬製剤のための酸化防止剤−安定剤系

Country Status (7)

Country Link
US (2) US5962488A (enExample)
EP (1) EP1067927B1 (enExample)
JP (1) JP2003522724A (enExample)
AT (1) ATE318598T1 (enExample)
CA (1) CA2327708A1 (enExample)
DE (1) DE69833684T2 (enExample)
WO (1) WO1999052529A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
KR20010101631A (ko) * 1999-01-21 2001-11-14 시오노 요시히코 페놀성 히드록시 화합물의 변색이 저해되는 의약 조성물
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
JPWO2007046411A1 (ja) * 2005-10-19 2009-04-23 大日本住友製薬株式会社 イソキサゾール化合物の安定化方法
DE102007025275A1 (de) * 2007-05-31 2008-12-04 Qiagen Gmbh Butendisäure oder deren Derivate zur Behandlung einer biologischen Probe
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
UY32008A (es) * 2008-07-28 2010-02-26 Takeda Pharmaceutical Composición farmacéutica
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
ES2428938T3 (es) * 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
PL2736495T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
LT2838512T (lt) 2012-04-18 2018-11-12 Grünenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 1個または複数の粒子を含有する改変防止(tamper−resistant)剤形
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
CN107750159B (zh) * 2015-06-23 2021-10-29 英特维特国际股份有限公司 用于消毒的饮用水的含有维生素的异噁唑啉溶液
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
MX2023003783A (es) * 2020-10-01 2023-04-26 Imago Biosciences Inc Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB679192A (en) * 1948-07-09 1952-09-17 Eastman Kodak Co Method of stabilizing fats and fatty oils against oxidation
GB682205A (en) * 1949-03-16 1952-11-05 Eastman Kodak Co Improvements in and relating to anti-oxidants for oils and fats
US4091091A (en) * 1973-11-08 1978-05-23 Eli Lilly And Company Stabilized nitroglycerin tablets
JPS5299242A (en) * 1976-02-12 1977-08-19 Tanabe Seiyaku Co Antiioxidant
JPS62153385A (ja) * 1985-12-27 1987-07-08 Riken Vitamin Co Ltd 酸化防止剤
US4837031A (en) * 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
DK0471515T3 (da) * 1990-08-15 1997-07-21 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronphtalener, 3-aminochromaner og 3-aminothiochromaner
JPH06500594A (ja) * 1991-01-07 1994-01-20 カビ ファルマシア アクチェボラーグ 多不飽和油の安定化のための天然酸化防止剤の組成物
US5077069A (en) * 1991-01-07 1991-12-31 Kabi Pharmacia Ab Composition of natural antioxidants for the stabilization of polyunsaturated oils
JPH05339154A (ja) * 1992-06-03 1993-12-21 Sagami Chem Res Center 肝機能改善剤
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
JPH0717855A (ja) * 1992-09-02 1995-01-20 Maruha Corp 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
PT725639E (pt) * 1993-10-25 2001-02-28 Merrell Pharma Inc Composicao farmaceutica estavel de terfenadina e ibuprofeno
JPH09194362A (ja) * 1996-01-19 1997-07-29 Bizen Kasei Kk ドコサヘキサエン酸及びエイコサペンタエン酸含有リン脂質を含む組成物
JP3941073B2 (ja) * 1996-03-01 2007-07-04 日本油脂株式会社 油脂組成物及びそれを含む食品
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives

Similar Documents

Publication Publication Date Title
JP2003522724A5 (enExample)
EP1067927A4 (en) ANTIOXIDANT STABILIZER SYSTEM FOR PHARMACEUTICAL FORMULATIONS
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
PL362443A1 (en) Mixtures or organic compounds for the treatmentof airway diseases
JP2001526218A5 (enExample)
IL101162A0 (en) Pharmaceutical compositions for oral administration comprising an indole derivative
RU98115774A (ru) Новые производные 19-нор-прегнена
PT1642885E (pt) Utilização de uma composição farmacêutica contendo um derviado de ácido para-aminofenilacético para o tratamento de estados inflamatórios do tracto gastrointestinal
KR950010890A (ko) 폐경기 증후군의 치료방법
RU2001111880A (ru) Композиции для перорального введения, содержащие луфенурон и нитенпирам, для борьбы с блохами
KR960041168A (ko) 베타-아드레날린 효능성 작용물질
JP2002519425A5 (enExample)
DE60121145D1 (de) Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln
KR0180232B1 (ko) 수난용성 약제를 함유하는 약학 조성물
SE9901573D0 (sv) New compounds
KR920002579A (ko) 종양치료 조성물 및 치료방법
HU9600266D0 (en) Pharmaceutical organic salt solutions for endonasal application
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
JP2003519228A5 (enExample)
MY125099A (en) Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid
JP2002539089A5 (enExample)
KR900016135A (ko) 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체
RU94044357A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования увеличения веса, индуцирования снижения веса или ингибирования аппетита
TR200103144T2 (tr) Yeni bileşikler
IL148196A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same